Loading organizations...
§ Private Profile · Oxford, Oxfordshire, United Kingdom
Perspectum is a technology company.
Perspectum is a precision health company that creates advanced, non-invasive imaging technologies for diagnostics and disease management. The company specializes in AI-driven solutions that provide quantitative assessments of health, enhancing clinical decision-making for metabolic diseases, liver conditions, diabetes, and cancer. Its suite of products aims to deliver comprehensive diagnostic insights and support personalized patient care through streamlined and accessible platforms.
The company was founded in 2012 by Rajarshi Banerjee, Professor Sir Michael Brady, and Dr. Matthew Robson. Dr. Banerjee, a medical doctor and an expert in MRI scanning, recognized the need for more precise and non-invasive tools to improve the diagnosis, treatment, and ongoing management of complex metabolic and liver diseases, particularly with the limitations of existing methods. This insight formed the foundation for Perspectum’s development of innovative imaging solutions.
Perspectum's products are utilized by clinicians in healthcare settings to gain deeper insights into patient health, enabling more informed diagnoses and tailored treatment plans. The company's vision is to advance precision medicine by empowering both patients and healthcare providers with accurate, data-driven assessments. It continues to focus on developing technologies that improve outcomes and patient engagement across critical disease areas, fostering a forward-looking approach to medical diagnostics.
Perspectum has raised $92.0M across 3 funding rounds.
Perspectum has raised $92.0M in total across 3 funding rounds.
Perspectum has raised $92.0M across 3 funding rounds. Most recently, it raised $19.0M Series C Extension in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 15, 2023 | $19M Series C Plus | Robert Lowenthal | — | Announced |
| Jan 1, 2023 | $37M Series C | Robert Lowenthal | Accomplice VC, Action Potential Venture Capital, Cofounders Capital, HealthQuest Capital, Saltagen Ventures, Sandbox Industries, Frederic Kerrest, Catherine Lewis LA Torre CBE | Announced |
| Apr 1, 2020 | $36M Series B | HealthQuest Capital, Thomas Hawes | Activate Venture Partners, Cofounders Capital, Primary Venture Partners, Sandbox Industries, SV Health Investors, Oxford Science Enterprises, University OF Oxford | Announced |
Perspectum has raised $92.0M in total across 3 funding rounds.
Perspectum's investors include Robert Lowenthal, Accomplice VC, Action Potential Venture Capital, Cofounders Capital, HealthQuest Capital, Saltagen Ventures, Sandbox Industries, Frederic Kerrest, Catherine Lewis La Torre CBE, Thomas Hawes, Activate Venture Partners, Primary Venture Partners.
Perspectum is a commercial-stage precision health technology company that develops AI-driven software for analyzing medical imaging, primarily multiparametric MRI, to extract biomarkers for diagnosing and monitoring chronic diseases like liver disease, diabetes, cancer, long COVID, and multi-organ pathologies.[1][2][4][6] It serves healthcare providers worldwide through a SaaS platform called the Perspectum Portal, enabling non-invasive, cost-effective diagnostics on existing MRI equipment at around 350 global locations, with a focus on early detection, personalized treatment, and therapy response monitoring.[1][4][5] The company solves the problem of incomplete insights from conventional diagnostics by providing integrated, actionable data intelligence, addressing a U.S. total addressable market over $30 billion for metabolic diseases, multi-organ issues, and cancer.[4][6] Perspectum demonstrates strong growth momentum, named the fastest-growing UK life sciences company in 2019 with international expansion to the U.S. and Singapore, $90.9M in total funding including a $55M round, and recent recognition like the 2024 Prix Galien USA nomination for its CoverScan multi-organ MRI technology.[3][5][6]
Perspectum was founded in 2012 in Oxford, United Kingdom, stemming from a groundbreaking University of Oxford study on multiparametric MRI for liver disease assessment, evolving from a startup into a global leader in digital medical imaging and diagnostics.[1][2] Led by renowned physicians and scientists with decades of research and clinical experience, the company has grown through innovations like LiverMultiScan for quantifying liver tissue, MRCP+ for biliary imaging, and patented iron-corrected T1 (cT1) biomarkers for NAFLD/NASH.[1][3] Early traction included adoption in over 40% of Phase 2 NASH trials, partnerships with drug companies, and government-funded UK imaging centers, fueling office openings in San Francisco, Singapore, and Dallas by 2019.[3]
Perspectum rides the precision medicine wave, leveraging AI and advanced imaging to shift diagnostics from invasive biopsies to non-invasive, data-rich alternatives amid rising chronic disease burdens like NAFLD/NASH (affecting 25%+ of the U.S. population) and demand for therapy monitoring in clinical trials.[1][3][4] Timing aligns with global healthcare digitization, AI-biotech convergence, and post-pandemic focus on long COVID/multi-organ issues, amplified by regulatory support for digital health and $50M UK imaging investments where Perspectum featured in 3 of 5 bids.[3][6] Market forces favoring it include exploding metabolic disease prevalence, pharma needs for biomarkers (e.g., 40% NASH trial usage), and SaaS scalability on ubiquitous MRI infrastructure, positioning Perspectum to influence ecosystems by democratizing high-quality care and accelerating drug development.[2][3][4]
Perspectum is poised for continued expansion with its CoverScan multi-organ platform and growing SaaS footprint, potentially capturing more of the $30B+ TAM through AI enhancements and global site activations.[4][5][6] Trends like federated AI for privacy-preserving diagnostics, personalized oncology/metabolic therapies, and Expo 2025 showcases will shape its path, evolving its influence from liver specialists to broad precision health leaders.[2][6] As imaging AI matures, expect deeper pharma integrations and regulatory wins, amplifying its role in making "the impossible possible" for patient outcomes—building on its vision of a better tomorrow through innovation.[1][6]